Tag: media

STOCKHOLM, Sweden, June 25, 2026 – AnaCardio, a clinical stage biopharmaceutical company developing novel drugs to treat heart failure, today announced the publication in The Lancet of results from its Phase 1b/2a GOAL-HF1 study evaluating AC01, a first-in-class, oral calcium-sensitising contractile agent, in patients with heart failure with reduced ejection fraction (HFrEF). The results showed a favourable safety and tolerability profile, dose-proportional pharmacokinetics with confirmed target engagement. In exploratory efficacy analyses, numerical rapid and sustained improvements in haemodynamics and cardiac structure and function were observed on top of optimised guideline-directed medical therapy (GDMT).

BEIJING, June 25, 2026 (GLOBE NEWSWIRE) -- DSC Holdings Ltd. (“DSC” or the “Company”) (NASDAQ: DSC), the AI application infrastructure for China’s used car industry, today announced that it has priced its initial public offering of 3,000,000 American depositary shares (“ADSs”) at US$17 per ADS, for a total offering size of approximately US$51 million, assuming the underwriters do not exercise their over-allotment option to purchase additional ADSs. Each ADS represents 20 Class A ordinary shares of the Company. The ADSs are expected to begin trading on the Nasdaq Global Market today under the ticker symbol “DSC.” The offering is expected to close on June 26, 2026, subject to customary closing conditions.

Hannover, Germany, June 25, 2026 (GLOBE NEWSWIRE) -- EMBARC Announces Its Intention to Collaborate with Insmed on Landmark Interventional Study Evaluating Disease Modification Potential of Brensocatib in Bronchiectasis
—Long-Term, Open-Label Study to Enroll Approximately 3,000 Patients Across Europe—